MX2022013838A - Compuestos heterociclicos como agonistas del receptor de activacion expresado en las celulas mieloides 2 y metodos de uso. - Google Patents

Compuestos heterociclicos como agonistas del receptor de activacion expresado en las celulas mieloides 2 y metodos de uso.

Info

Publication number
MX2022013838A
MX2022013838A MX2022013838A MX2022013838A MX2022013838A MX 2022013838 A MX2022013838 A MX 2022013838A MX 2022013838 A MX2022013838 A MX 2022013838A MX 2022013838 A MX2022013838 A MX 2022013838A MX 2022013838 A MX2022013838 A MX 2022013838A
Authority
MX
Mexico
Prior art keywords
myeloid cells
receptor expressed
agonists
methods
compounds
Prior art date
Application number
MX2022013838A
Other languages
English (en)
Inventor
Vincent Santora
Ryan D White
Lara C Czabaniuk
Timothy Hopper
Jonathan B Houze
Gwenaella Rescourio
Haoxuan Wang
Alice R Wong
Yongwei Wu
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2022013838A publication Critical patent/MX2022013838A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente descripción proporciona compuestos de la Fórmula I, útiles para la activación del receptor de activación expresado en células mieloides 2 ("TREM2"). (ver formula) I la presente descripción también proporciona composiciones farmacéuticas que comprenden los compuestos, usos de los compuestos, y composiciones para el tratamiento, por ejemplo, de un trastorno neurodegenerativo. además, la descripción proporciona productos intermedios útiles en la síntesis de compuestos de la Fórmula I.
MX2022013838A 2020-05-04 2021-05-04 Compuestos heterociclicos como agonistas del receptor de activacion expresado en las celulas mieloides 2 y metodos de uso. MX2022013838A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063019768P 2020-05-04 2020-05-04
PCT/US2021/030719 WO2021226135A1 (en) 2020-05-04 2021-05-04 Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use

Publications (1)

Publication Number Publication Date
MX2022013838A true MX2022013838A (es) 2023-02-22

Family

ID=78468393

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022013838A MX2022013838A (es) 2020-05-04 2021-05-04 Compuestos heterociclicos como agonistas del receptor de activacion expresado en las celulas mieloides 2 y metodos de uso.

Country Status (17)

Country Link
US (3) US20240190863A1 (es)
EP (1) EP4146220A4 (es)
JP (1) JP2023524806A (es)
KR (1) KR20230020983A (es)
CN (1) CN116322696A (es)
AU (1) AU2021267161A1 (es)
BR (1) BR112022022338A2 (es)
CA (1) CA3182541A1 (es)
CL (1) CL2022003041A1 (es)
CO (1) CO2022015927A2 (es)
CR (1) CR20220559A (es)
CU (1) CU20220065A7 (es)
EC (1) ECSP22089520A (es)
IL (1) IL297845A (es)
MX (1) MX2022013838A (es)
PE (1) PE20230609A1 (es)
WO (1) WO2021226135A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022022338A2 (pt) * 2020-05-04 2023-01-10 Amgen Inc Compostos heterocíclicos como receptor desencadeador expresso em agonistas de células mieloides 2 e métodos de uso
TW202334141A (zh) * 2021-11-09 2023-09-01 美商維佳神經科學有限公司 作為骨髓細胞上表現之觸發受體２促效劑之雜環化合物及其使用方法
WO2023086801A1 (en) * 2021-11-09 2023-05-19 Vigil Neuroscience, Inc. Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use
WO2024008722A2 (en) * 2022-07-04 2024-01-11 Muna Therapeutics Aps Trem2 modulators

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2940972A (en) 1957-06-27 1960-06-14 Thomae Gmbh Dr K Tri-and tetra-substituted pteridine derivatives
US2963481A (en) 1959-11-27 1960-12-06 Smith Kline French Lab 6-pteridinecarboxylic acid esters
AU1599395A (en) 1994-01-03 1995-08-01 Cocensys, Inc. 8-aza, 6-aza and 6,8-diaza-1,4-dihydroquinoxaline-2,3-diones and the use thereof as antagonists for the glycine/nmda receptor
EP1028950B1 (en) 1997-10-28 2003-05-02 Warner-Lambert Company LLC 7-substituted quinazolin-2,4-diones useful as antibacterial agents
CA2431904A1 (en) 2000-12-20 2002-08-01 Merck & Co., Inc. (halo-benzo carbonyl)heterocyclo fused phenyl p38 kinase inhibiting agents
JP2003005355A (ja) 2001-06-20 2003-01-08 Fuji Photo Film Co Ltd 電子線又はｘ線用ネガ型レジスト組成物
WO2005007099A2 (en) 2003-07-10 2005-01-27 Imclone Systems Incorporated Pkb inhibitors as anti-tumor agents
WO2005039587A1 (en) 2003-10-17 2005-05-06 4 Aza Bioscience Nv Heterocycle-substituted pteridine derivatives and their use in therapy
MXPA06005019A (es) 2003-11-03 2006-07-06 Warner Lambert Co Nuevos inhibidores de la recaptacion de norpinefrina para el tratamiento de transtornos del sistema nervioso central.
WO2005077905A1 (ja) * 2004-02-13 2005-08-25 Banyu Pharmaceutical Co., Ltd. 縮環４－オキソ－ピリミジン誘導体
EP1737831B1 (en) * 2004-04-02 2013-05-22 Prana Biotechnology Limited Neurologically-active compounds
US20070054916A1 (en) 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
WO2006128129A2 (en) 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Method for treating cancer
US20070032493A1 (en) 2005-05-26 2007-02-08 Synta Pharmaceuticals Corp. Method for treating B cell regulated autoimmune disorders
KR100659088B1 (ko) 2005-07-15 2006-12-21 삼성에스디아이 주식회사 디플루오로피리딘계 화합물 및 이를 이용한 유기 발광 소자
WO2007038331A2 (en) 2005-09-23 2007-04-05 Smithkline Beecham Corporation Novel chemical compounds
EP1996191A4 (en) 2006-03-02 2010-05-19 Glaxosmithkline Llc THIAZOLONE AS A PI3 KINASE INHIBITOR
US7855194B2 (en) 2006-03-27 2010-12-21 Hoffmann-La Roche Inc. Pyrimidine, quinazoline, pteridine and triazine derivatives
WO2008003149A2 (en) 2006-07-06 2008-01-10 Gilead Sciences , Inc. Substituted pteridines for the treatment and prevention of viral infections
US7635683B2 (en) 2006-08-04 2009-12-22 Enanta Pharmaceuticals, Inc. Quinoxalinyl tripeptide hepatitis C virus inhibitors
MY148688A (en) 2006-08-23 2013-05-31 Kudos Pharm Ltd 2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors
ES2442847T3 (es) 2007-04-18 2014-02-13 Amgen, Inc Quinolonas y azaquinolonas que inhiben la prolil hidroxilasa
JP2011500657A (ja) 2007-10-15 2011-01-06 アストラゼネカ アクチボラグ 組合せ０５９
WO2009100406A2 (en) 2008-02-07 2009-08-13 Synta Pharmaceuticals Corp. Topical formulations for the treatment of psoriasis
US8298825B1 (en) 2008-08-25 2012-10-30 The General Hospital Corporation TGF-beta receptor inhibitors to enhance direct reprogramming
US20120021519A1 (en) 2008-09-19 2012-01-26 Presidents And Fellows Of Harvard College Efficient induction of pluripotent stem cells using small molecule compounds
DK2356109T3 (en) 2008-10-10 2017-03-13 Vm Discovery Inc COMPOSITIONS AND PROCEDURES FOR TREATING DISEASES IN CONNECTION WITH ALCOHOL CONSUMPTION, Pain and OTHER DISEASES
CA2755253A1 (en) 2009-03-18 2010-09-23 Schering Corporation Bicyclic compounds as inhibitors of diacylglycerol acyltransferase
US8691187B2 (en) 2009-03-23 2014-04-08 Eli Lilly And Company Imaging agents for detecting neurological disorders
WO2011014039A1 (en) 2009-07-31 2011-02-03 Rohm And Haas Electronic Materials Korea Ltd. Novel organic electroluminescent compounds and organic electroluminescent device using the same
WO2011037731A1 (en) 2009-09-25 2011-03-31 Anacor Pharmaceuticals, Inc. Boron containing small molecules
US9126952B2 (en) 2010-03-16 2015-09-08 Merck Patent Gmbh Morpholinylquinazolines
US9139592B2 (en) 2010-06-14 2015-09-22 Trt Pharma Inc. Modulators of Nrf2 and uses thereof
CN102887895B (zh) 2011-07-22 2016-08-24 山东轩竹医药科技有限公司 吡啶并嘧啶类mTOR抑制剂
KR101497124B1 (ko) 2011-11-28 2015-03-06 덕산네오룩스 주식회사 유기전기소자용 화합물, 이를 포함하는 유기전기소자 및 그 전자 장치
EA039373B1 (ru) 2012-02-08 2022-01-19 Янссен Сайенсиз Айрлэнд Юси Производные пиперидино-пиримидина для лечения вирусных инфекций
CN103374021B (zh) 2012-04-21 2015-10-28 通化济达医药有限公司 含有锌结合基的吡啶并嘧啶类HDAC和mTOR抑制剂
WO2014146249A1 (en) 2013-03-19 2014-09-25 Merck Sharp & Dohme Corp. Geminally substituted cyanoethylpyrazolo pyridones as janus kinase inhibitors
US9745297B2 (en) 2013-07-30 2017-08-29 Boehringer Ingelheim International Gmbh Compounds as modulators of RORC
CA2931589C (en) 2013-12-09 2022-01-04 Ucb Biopharma Sprl Fused bicyclic heteroaromatic derivatives as modulators of tnf activity
KR20150080966A (ko) 2014-01-02 2015-07-13 최돈수 유기 전기 발광 소자용 발광 재료, 이를 이용한 유기 전기 발광 소자 및 유기 전기 발광 소자용 재료
KR20160060572A (ko) 2014-11-19 2016-05-30 주식회사 엠비케이 유기 발광 화합물, 잉크 조성물, 유기 발광 소자 및 전자 기기
US10403826B2 (en) 2015-05-07 2019-09-03 Universal Display Corporation Organic electroluminescent materials and devices
EP3335254B1 (de) 2015-08-11 2020-04-08 Merck Patent GmbH Materialien für organische elektrolumineszenzvorrichtungen
WO2017031427A1 (en) 2015-08-19 2017-02-23 3-V Biosciences, Inc. COMPOUNDS AND METHODS FOR INHIBITING mTOR
KR102606277B1 (ko) 2016-04-06 2023-11-27 삼성디스플레이 주식회사 유기 발광 소자
US10573692B2 (en) 2016-04-06 2020-02-25 Samsung Display Co., Ltd. Organic light-emitting device having a sealing thin film encapsulation portion
SI3442947T1 (sl) 2016-04-15 2023-10-30 Epizyme, Inc. Z aminom substituirane arilne ali heteroarilne spojine kot inhibitorji ehmt1 in ehmt2
MX2019003790A (es) 2016-10-04 2019-09-26 Enanta Pharm Inc Analogos de isoxazol como agonistas de fxr y metodos de uso de los mismos.
US11283028B2 (en) 2016-10-05 2022-03-22 Rohm And Haas Electronic Materials Korea Ltd. Organic electroluminescent compound and organic electroluminescent device comprising the same
WO2018108110A1 (zh) 2016-12-13 2018-06-21 广州华睿光电材料有限公司 金属有机配合物及其应用、混合物、有机电子器件
TW201843143A (zh) 2017-03-13 2018-12-16 德商麥克專利有限公司 含有芳基胺結構之化合物
WO2018169352A1 (en) 2017-03-16 2018-09-20 Rohm And Haas Electronic Materials Korea Ltd. Organic electroluminescent device
KR102335935B1 (ko) 2017-03-22 2021-12-06 덕산네오룩스 주식회사 유기전기소자용 화합물, 이를 이용한 유기전기소자 및 그 전자 장치
WO2018183923A1 (en) 2017-03-31 2018-10-04 Epizyme, Inc. Methods of using ehmt2 inhibitors
KR102389204B1 (ko) 2017-04-18 2022-04-21 덕산네오룩스 주식회사 유기전기 소자용 화합물, 이를 이용한 유기전기소자 및 그 전자 장치
EP3612181A4 (en) 2017-04-21 2021-01-06 Epizyme, Inc. COMBINATION THERAPIES WITH EHMT2 INHIBITORS
WO2018204765A1 (en) 2017-05-05 2018-11-08 Pairnomix, Llc Methods of treating epilepsy and kcnq2 related conditions
WO2018227228A1 (en) 2017-06-13 2018-12-20 Commonwealth Scientific And Industrial Research Organisation Antiviral drugs
JPWO2019065516A1 (ja) 2017-09-26 2020-09-10 日本曹達株式会社 キノリン化合物および農園芸用殺菌剤
EP3697420A4 (en) 2017-10-18 2021-11-24 Epizyme, Inc. METHODS OF USING EHMT2 INHIBITORS IN IMMUNOTHERAPIES
US20210260040A1 (en) 2017-10-18 2021-08-26 Epizyme, Inc. Methods of using ehmt2 inhibitors in treating or preventing blood disorders
CN108484680B (zh) 2018-01-31 2020-12-11 马鞍山南京大学高新技术研究院 一类双硫代芳环/芳杂环磷酸化合物作为辅助配体的铱配合物
EP3788038B1 (en) 2018-05-04 2023-10-11 Amgen Inc. Kras g12c inhibitors and methods of using the same
US20200075870A1 (en) 2018-08-22 2020-03-05 Universal Display Corporation Organic electroluminescent materials and devices
CN109265457A (zh) 2018-11-01 2019-01-25 中国药科大学 一种利用氧化芳构化构建吡啶并嘧啶二酮骨架的新方法
EP3966208A4 (en) 2019-05-10 2024-01-03 Antidote Ip Holdings Llc COMPOUNDS AND METHODS FOR TREATING CANCER
CN110283171A (zh) 2019-07-17 2019-09-27 鼎泰(南京)临床医学研究有限公司 一类含有吡啶并嘧啶-4-胺类结构的化合物、药物组合物以及其应用
US11820783B2 (en) 2019-09-06 2023-11-21 Universal Display Corporation Organic electroluminescent materials and devices
TW202208355A (zh) 2020-05-04 2022-03-01 美商安進公司 作為骨髓細胞觸發受體2促效劑之雜環化合物及使用方法
BR112022022338A2 (pt) * 2020-05-04 2023-01-10 Amgen Inc Compostos heterocíclicos como receptor desencadeador expresso em agonistas de células mieloides 2 e métodos de uso
CN111454265B (zh) 2020-05-07 2021-08-24 宁波卢米蓝新材料有限公司 一种稠杂环化合物及其制备方法和应用

Also Published As

Publication number Publication date
PE20230609A1 (es) 2023-04-13
JP2023524806A (ja) 2023-06-13
EP4146220A1 (en) 2023-03-15
KR20230020983A (ko) 2023-02-13
CR20220559A (es) 2023-08-18
CU20220065A7 (es) 2023-06-13
CA3182541A1 (en) 2021-11-11
US20240190863A1 (en) 2024-06-13
US11718617B2 (en) 2023-08-08
CN116322696A (zh) 2023-06-23
IL297845A (en) 2023-01-01
CL2022003041A1 (es) 2023-07-14
EP4146220A4 (en) 2024-05-29
BR112022022338A2 (pt) 2023-01-10
US20230144581A1 (en) 2023-05-11
WO2021226135A1 (en) 2021-11-11
CO2022015927A2 (es) 2023-01-26
ECSP22089520A (es) 2023-02-28
US20240124446A1 (en) 2024-04-18
AU2021267161A1 (en) 2022-12-08

Similar Documents

Publication Publication Date Title
CR20220560A (es) Compuestos heterocíclicos como agonistas del receptor de activación expresado en las células mieloides 2 y métodos de uso
MX2022013838A (es) Compuestos heterociclicos como agonistas del receptor de activacion expresado en las celulas mieloides 2 y metodos de uso.
US11052070B2 (en) Riluzole prodrugs and their use
UA85576C2 (ru) Тетразольные соединения и их применение в качестве метаботропических антагонистов рецепторов глутамата
HK1098460A1 (en) Fused hetrocyclic compounds and their use as metabotropic receptor antagonists for the treatment of gastrointestinal disorders
MX2007008614A (es) Peptidos con actividad agonista del receptor del neuropeptido-2 (y2r).
HRP20080689T3 (en) Imidazoline derivatives having cb1-antagonistic activity
CR20220371A (es) Agonistas heterocíclicos de glp-1
TW200716528A (en) Cyclopropanecarboxamide derivatives
ZA202306748B (en) Glp-1r receptor agonist compound and use thereof
MXPA05010824A (es) Compuestos biciclicos como antagonistas del receptor nr2b.
MEP6808A (xx) Priperidinoilpirodolini agonisti receptora menalokortina tipa 4
DE602006004882D1 (de) Azabicycloä3.1.0ühexylphenylderivate als modulatoren von dopamin-d3-rezeptoren
EP3790867A1 (en) Kdm1a inhibitors for the treatment of disease
MX2008001606A (es) Piperazinas substituidas como antagonistas de receptor de glutamato metabotropico.
MXPA05007115A (es) Nuevos agonistas inversos del receptor cb 1.
TW200508207A (en) New benzimidazole derivatives
GB0701366D0 (en) Novel pharmaceutical compositions
TW200740781A (en) Novel compounds
SE0403171D0 (sv) New compounds
MX2022000550A (es) Imidazopirimidinas como inhibidores de eed y uso de estas.
MY138547A (en) N-substituted nonaryl-heterocyclic nmda/nr2b antagonists
TW200720262A (en) Novel compounds ii
JOP20220084A1 (ar) مشتقات 5-أوكسا- 2- آزا سبيرو [3.4] أوكتان كناهضات لـ m4
JOP20220082A1 (ar) مشتقات 2- آزا سبيرو [3.4] أوكتان كناهضات لـ m4